Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topotecan plus cyclophosphamide added to standard treatment for children with advanced retinoblastoma in Tanzania
ISRCTN63331029Phase 4Not yet recruiting
- Sponsor
- London School of Hygiene & Tropical Medicine
- Start
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of topotecan and cyclophosphamide in retinoblastoma (Rb) (2 arms), sponsored by London School of Hygiene & Tropical Medicine. Primary endpoint: Overall survival. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
topotecancyclophosphamide
03
Conditions
retinoblastoma (Rb)
Beyond the preview
Go deeper on ISRCTN63331029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN63331029.